These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2274926)

  • 21. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Granulocyte elastase, tumor necrosis factor-alpha and urokinase levels as prognostic markers in severe infection.
    Philippé J; Dooijewaard G; Offner F; Turion P; Baele G; Leroux-Roels G
    Thromb Haemost; 1992 Jul; 68(1):19-23. PubMed ID: 1514167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans.
    Chia S; Qadan M; Newton R; Ludlam CA; Fox KA; Newby DE
    Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):695-701. PubMed ID: 12692009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro.
    Louise CB; Obrig TG
    Microvasc Res; 1994 May; 47(3):377-87. PubMed ID: 8084301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of pro- and antifibrinolytic properties of human peritoneal mesothelial cells by transforming growth factor beta1 (TGF-beta1), tumor necrosis factor alpha (TNF-alpha) and interleukin 1beta (IL-1beta).
    Tietze L; Elbrecht A; Schauerte C; Klosterhalfen B; Amo-Takyi B; Gehlen J; Winkeltau G; Mittermayer C; Handt S
    Thromb Haemost; 1998 Feb; 79(2):362-70. PubMed ID: 9493592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross talk of tumor necrosis factor-alpha and the renin-angiotensin system in tumor necrosis factor-alpha-induced plasminogen activator inhibitor-1 production from hepatocytes.
    Takeshita Y; Takamura T; Ando H; Hamaguchi E; Takazakura A; Matsuzawa-Nagata N; Kaneko S
    Eur J Pharmacol; 2008 Jan; 579(1-3):426-32. PubMed ID: 18078928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
    Robinson SD; Dawson P; Ludlam CA; Boon NA; Newby DE
    Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [TNF-alpha and carbohydrate and lipid parameters in overweight and obese children].
    Goral J
    Ann Acad Med Stetin; 2008; 54(2):14-21. PubMed ID: 19374226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.
    Takeshita Y; Takamura T; Hamaguchi E; Shimizu A; Ota T; Sakurai M; Kaneko S
    Metabolism; 2006 Nov; 55(11):1464-72. PubMed ID: 17046548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions.
    Alemán C; Alegre J; Monasterio J; Segura RM; Armadans L; Anglés A; Varela E; Ruiz E; Fernández de Sevilla T
    Clin Sci (Lond); 2003 Nov; 105(5):601-7. PubMed ID: 12826021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies.
    Colucci M; Altomare DF; Chetta G; Triggiani R; Cavallo LG; Semeraro N
    Thromb Haemost; 1988 Aug; 60(1):25-9. PubMed ID: 3142090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Peculiar increase of plasma plasminogen activator inhibitor 1 levels in patients with hemophagocytic histiocytosis].
    Shimmyozu K; Kadokura N; Itoyama T; Tara M; Maruyama I; Osame M
    Rinsho Ketsueki; 1990 Jan; 31(1):127-8. PubMed ID: 2313902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Relationship of lipoprotein(a) to fibrinolytic activities in healthy subjects].
    Xiong X; Zhao S; Wang Z; Lo L; Huang Q
    Hunan Yi Ke Da Xue Xue Bao; 1998; 23(6):555-7. PubMed ID: 10806767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential changes in plasma cytokine and endotoxin levels in cirrhotic patients with bacterial infection.
    Wang SS; Lee FY; Chan CC; Lu RH; Chao Y; Lin HC; Wu SL; Tsai YT; Lee SD
    Clin Sci (Lond); 2000 Apr; 98(4):419-25. PubMed ID: 10731475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans.
    Dofferhoff AS; Bom VJ; de Vries-Hospers HG; van Ingen J; vd Meer J; Hazenberg BP; Mulder PO; Weits J
    Crit Care Med; 1992 Feb; 20(2):185-92. PubMed ID: 1371097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia].
    Okopień B; Cwalina Ł; Haberka M; Kowalski J; Zieliński M; Szwed Z; Kalina Z; Herman ZS
    Pol Merkur Lekarski; 2002 Dec; 13(78):465-9. PubMed ID: 12666442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Inhibitor of the extrinsic pathway of coagulation and cytokines in patients with sepsis].
    Páramo JA; Montes R; Hermida MJ; Panizo C; Chordá C; Rocha E
    Sangre (Barc); 1995 Feb; 40(1):59-62. PubMed ID: 7716674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease.
    Brandtzaeg P; Joø GB; Brusletto B; Kierulf P
    Thromb Res; 1990 Jan; 57(2):271-8. PubMed ID: 2315889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.